首页 > 最新文献

Minerva obstetrics and gynecology最新文献

英文 中文
Cerebrospinal fluid as vaginal discharge: ventriculoperitoneal shunt migration following Cesarean section. 脑脊液作为阴道分泌物:剖宫产术后脑室-腹腔分流术的迁移。
IF 1.8 Q2 Medicine Pub Date : 2023-10-01 DOI: 10.23736/S2724-606X.22.05091-6
Steffanie R Wright, Lauryn C Gabby, Brian T Nguyen

Congenital hydrocephalus was once a permanently disabling and even fatal disease. With the advent of ventriculoperitoneal shunts, affected women are now surviving to their reproductive years and beyond. Pregnancy outcomes in this population are generally positive. However due to possible shunt complications, including infection, migration, and organ perforation, perinatal care for pregnant individuals with a ventriculoperitoneal shunt is complex and requires input from both obstetric and neurosurgical providers. We present the case of a 28-year-old G1P1 with a history of congenital hydrocephalus and ventriculoperitoneal shunt who presented to the emergency department at two months postpartum with clear fluid leaking from her vagina. The shunt's distal end had migrated and perforated the uterus causing cerebrospinal fluid to leak into the uterine cavity. Surgical repair was required of both the uterine hysterotomy and ventriculoperitoneal shunt, and the patient's symptoms ultimately resolved. Patients with a history of shunt placement who later undergo abdominal surgery, including cesarean section, are at risk for shunt complications. Shunt-dependent patients presenting in the post-partum period with new neurological or abdominopelvic complaints should undergo evaluation by a multidisciplinary team.

先天性脑积水曾经是一种永久致残甚至致命的疾病。随着脑室腹膜分流术的出现,受影响的女性现在可以活到生育年龄及以后。这一人群的妊娠结局通常是积极的。然而,由于可能出现分流并发症,包括感染、迁移和器官穿孔,患有脑室-腹腔分流的孕妇的围产期护理很复杂,需要产科和神经外科医生的投入。我们报告了一例28岁的G1P1患者,她有先天性脑积水和脑室-腹腔分流术的病史,产后两个月时因阴道渗出透明液体而到急诊科就诊。分流器的远端移位并刺穿子宫,导致脑脊液泄漏到子宫腔。子宫子宫切开术和脑室腹膜分流术都需要手术修复,患者的症状最终得到了缓解。有分流安置史的患者,如果后来接受腹部手术,包括剖宫产,则有发生分流并发症的风险。分流依赖型患者在产后出现新的神经系统或腹盆腔疾病,应接受多学科团队的评估。
{"title":"Cerebrospinal fluid as vaginal discharge: ventriculoperitoneal shunt migration following Cesarean section.","authors":"Steffanie R Wright,&nbsp;Lauryn C Gabby,&nbsp;Brian T Nguyen","doi":"10.23736/S2724-606X.22.05091-6","DOIUrl":"https://doi.org/10.23736/S2724-606X.22.05091-6","url":null,"abstract":"<p><p>Congenital hydrocephalus was once a permanently disabling and even fatal disease. With the advent of ventriculoperitoneal shunts, affected women are now surviving to their reproductive years and beyond. Pregnancy outcomes in this population are generally positive. However due to possible shunt complications, including infection, migration, and organ perforation, perinatal care for pregnant individuals with a ventriculoperitoneal shunt is complex and requires input from both obstetric and neurosurgical providers. We present the case of a 28-year-old G1P1 with a history of congenital hydrocephalus and ventriculoperitoneal shunt who presented to the emergency department at two months postpartum with clear fluid leaking from her vagina. The shunt's distal end had migrated and perforated the uterus causing cerebrospinal fluid to leak into the uterine cavity. Surgical repair was required of both the uterine hysterotomy and ventriculoperitoneal shunt, and the patient's symptoms ultimately resolved. Patients with a history of shunt placement who later undergo abdominal surgery, including cesarean section, are at risk for shunt complications. Shunt-dependent patients presenting in the post-partum period with new neurological or abdominopelvic complaints should undergo evaluation by a multidisciplinary team.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41135746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstetric vascular Doppler velocimetry: clinical applications and overuses. 产科血管多普勒测速仪:临床应用和过度使用。
IF 1.8 Q2 Medicine Pub Date : 2023-10-01 Epub Date: 2023-05-04 DOI: 10.23736/S2724-606X.23.05164-3
Christopher A Enakpene, Maria E Canci, Gary Ventolini

A safe and non-intrusive assessment of fetal health is not only crucial in low-risk gestations, but it is also the standard of care in high-risk pregnancies. Therefore, measuring blood flow across different vessels with non-invasive ultrasound methods has been accurately and painstakingly studied and published. Amongst these state-of-the-art techniques, umbilical artery (blood flow) Doppler velocimetry (UADV) has allowed for fetal well-being follow-ups and assess uteroplacental function, which obtains a more complete and clearer picture; particularly in regard to complicated pregnancies. Additionally, there are other modalities with diverse clinical applications that have emerged, including their clinical and research utilization in conditions such as fetal growth restriction (FGR), preeclampsia, fetal anemia, monochorionic twins vascular blood flow mismatch such as is in twin-to-twin transfusion syndrome, twin anemia polycythemia sequence, and twin reverse arterial perfusion sequence. Nevertheless, their applications regarding various other maternal-fetal diagnoses in the same way as premature births and/or multiple gestation surveillance have not been reported to hold strong clinical evidence. With that in regard, the purpose of this unique study was to give update of the multiple clinical applications of this very important obstetrical tool. Additionally, to review the pathophysiology as well as revisit their reported significant valid uses and occasional overuses. We also delved into quality control measures as related to the application of Doppler in obstetrics. Lastly, it is essential to look through and reflect on the future developments of this valuable, non-invasive, high-risk marvelous modern device.

对胎儿健康进行安全、非侵入性的评估不仅在低风险妊娠中至关重要,而且也是高风险妊娠的护理标准。因此,用非侵入性超声方法测量不同血管的血流已经得到了准确而细致的研究和发表。在这些最先进的技术中,脐动脉(血流)多普勒测速仪(UADV)可以进行胎儿健康随访和评估子宫胎盘功能,从而获得更完整、更清晰的图像;特别是在复杂妊娠方面。此外,还出现了其他具有不同临床应用的模式,包括它们在胎儿生长受限(FGR)、先兆子痫、胎儿贫血、单核细胞性双胎血管血流失配(如双胎输血综合征)、双胎贫血红细胞增多症序列、,和双反向动脉灌注序列。然而,它们在各种其他母婴诊断方面的应用,与早产和/或多胎妊娠监测一样,尚未被报道具有强有力的临床证据。在这方面,这项独特研究的目的是更新这一非常重要的产科工具的多种临床应用。此外,回顾病理生理学,并重新审视其报告的显著有效使用和偶尔过度使用。我们还深入探讨了与多普勒在产科应用相关的质量控制措施。最后,有必要回顾和反思这种有价值、无创、高风险的神奇现代设备的未来发展。
{"title":"Obstetric vascular Doppler velocimetry: clinical applications and overuses.","authors":"Christopher A Enakpene,&nbsp;Maria E Canci,&nbsp;Gary Ventolini","doi":"10.23736/S2724-606X.23.05164-3","DOIUrl":"10.23736/S2724-606X.23.05164-3","url":null,"abstract":"<p><p>A safe and non-intrusive assessment of fetal health is not only crucial in low-risk gestations, but it is also the standard of care in high-risk pregnancies. Therefore, measuring blood flow across different vessels with non-invasive ultrasound methods has been accurately and painstakingly studied and published. Amongst these state-of-the-art techniques, umbilical artery (blood flow) Doppler velocimetry (UADV) has allowed for fetal well-being follow-ups and assess uteroplacental function, which obtains a more complete and clearer picture; particularly in regard to complicated pregnancies. Additionally, there are other modalities with diverse clinical applications that have emerged, including their clinical and research utilization in conditions such as fetal growth restriction (FGR), preeclampsia, fetal anemia, monochorionic twins vascular blood flow mismatch such as is in twin-to-twin transfusion syndrome, twin anemia polycythemia sequence, and twin reverse arterial perfusion sequence. Nevertheless, their applications regarding various other maternal-fetal diagnoses in the same way as premature births and/or multiple gestation surveillance have not been reported to hold strong clinical evidence. With that in regard, the purpose of this unique study was to give update of the multiple clinical applications of this very important obstetrical tool. Additionally, to review the pathophysiology as well as revisit their reported significant valid uses and occasional overuses. We also delved into quality control measures as related to the application of Doppler in obstetrics. Lastly, it is essential to look through and reflect on the future developments of this valuable, non-invasive, high-risk marvelous modern device.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9411317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Invasive prenatal diagnosis in the era of cell-free fetal DNA: experience at a single center. 无细胞胎儿DNA时代的侵入性产前诊断:单一中心的经验。
IF 1.8 Q2 Medicine Pub Date : 2023-10-01 DOI: 10.23736/S2724-606X.22.05042-4
Ilaria Ponziani, Marta Pallottini, Giulia Masini, Chiara Franchi, Silvia Balli, Lucia Pasquini

Background: We aimed to assess procedure-related risk of fetal loss associated with amniocentesis and chorionic villus sampling and compare amniocentesis and chorionic villus sampling with cell-free fetal DNA in identifying chromosomal abnormalities.

Methods: A retrospective observational study on 4712 women with singleton pregnancy who underwent invasive prenatal diagnosis, from January 2010 to December 2019. Postprocedural miscarriage rate (before 24+0 weeks gestation) was determined for the whole population and for the group of women aged ≥35 years who underwent the procedure for the sole maternal age.

Results: Miscarriage rate following amniocentesis and chorionic villus sampling were 0.50% and 1.25%, respectively. In our population of women undergoing invasive procedure for advanced maternal age cell-free fetal DNA would have identified only the 49 cases of trisomy 21, 13 and 18, whereas the other 21 more subtle chromosomal anomalies, diagnosed by amniocentesis and chorionic villus sampling, would have been missed.

Conclusions: Patients who opt for cell-free fetal DNA test should be informed of the screening nature of the test and the possibility of false positive results. Invasive prenatal testing has probably lower risks than previously reported and has unquestionable advantages such as the certainty of diagnosis and the ability to detect a higher number of chromosomal abnormalities, when compared with cell-free fetal DNA.

背景:我们旨在评估与羊水穿刺和绒毛膜取样相关的胎儿丢失的手术相关风险,并将羊水穿刺和绒毛膜绒毛取样与无细胞胎儿DNA进行比较,以确定染色体异常。方法:对2010年1月至2019年12月接受侵入性产前诊断的4712名单胎妊娠妇女进行回顾性观察研究。测定了整个人群和年龄≥35岁的女性组的术后流产率(妊娠24+0周前),这些女性在唯一的产妇年龄接受了手术。结果:羊水穿刺和绒毛取样后流产率分别为0.50%和1.25%。在我们接受高龄产妇侵入性手术的女性群体中,无细胞胎儿DNA只能识别出49例21、13和18三体,而通过羊水穿刺和绒毛取样诊断的其他21例更细微的染色体异常则会被遗漏。结论:选择无细胞胎儿DNA检测的患者应了解检测的筛查性质和假阳性结果的可能性。与无细胞胎儿DNA相比,侵入性产前检测的风险可能比以前报道的要低,并且具有毋庸置疑的优势,如诊断的确定性和检测更多染色体异常的能力。
{"title":"Invasive prenatal diagnosis in the era of cell-free fetal DNA: experience at a single center.","authors":"Ilaria Ponziani,&nbsp;Marta Pallottini,&nbsp;Giulia Masini,&nbsp;Chiara Franchi,&nbsp;Silvia Balli,&nbsp;Lucia Pasquini","doi":"10.23736/S2724-606X.22.05042-4","DOIUrl":"https://doi.org/10.23736/S2724-606X.22.05042-4","url":null,"abstract":"<p><strong>Background: </strong>We aimed to assess procedure-related risk of fetal loss associated with amniocentesis and chorionic villus sampling and compare amniocentesis and chorionic villus sampling with cell-free fetal DNA in identifying chromosomal abnormalities.</p><p><strong>Methods: </strong>A retrospective observational study on 4712 women with singleton pregnancy who underwent invasive prenatal diagnosis, from January 2010 to December 2019. Postprocedural miscarriage rate (before 24<sup>+0</sup> weeks gestation) was determined for the whole population and for the group of women aged ≥35 years who underwent the procedure for the sole maternal age.</p><p><strong>Results: </strong>Miscarriage rate following amniocentesis and chorionic villus sampling were 0.50% and 1.25%, respectively. In our population of women undergoing invasive procedure for advanced maternal age cell-free fetal DNA would have identified only the 49 cases of trisomy 21, 13 and 18, whereas the other 21 more subtle chromosomal anomalies, diagnosed by amniocentesis and chorionic villus sampling, would have been missed.</p><p><strong>Conclusions: </strong>Patients who opt for cell-free fetal DNA test should be informed of the screening nature of the test and the possibility of false positive results. Invasive prenatal testing has probably lower risks than previously reported and has unquestionable advantages such as the certainty of diagnosis and the ability to detect a higher number of chromosomal abnormalities, when compared with cell-free fetal DNA.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41133481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaginal colonization of women after oral administration of Lactobacillus crispatus strain NTCVAG04 from the human microbiota. 口服来自人类微生物群的脆乳杆菌菌株NTCVAG04后妇女的阴道定植。
IF 1.8 Q2 Medicine Pub Date : 2023-10-01 Epub Date: 2022-06-08 DOI: 10.23736/S2724-606X.22.05087-4
Vincenzo DE Leo, Elisa Lazzeri, Laura Governini, Anna M Cuppone, Lorenzo Colombini, Lucia Teodori, Giorgio Ciprandi, Francesco Iannelli, Gianni Pozzi

Background: The genomic approach has deeply changed the microbiology perspective, mainly concerning the microbioma identification. In this regard, some microbes colonize the healthy vagina. Vaginitis is a common gynecological ailment and includes bacterial vaginosis (BV), usually caused by local dysbiosis, such as a microbiota imbalance. Lactobacilli are the most prevalent bacteria colonizing the healthy vagina, so guaranteeing local eubiosis. In particular, vaginal colonization by L. crispatus is associated with low susceptibility to BV. Therefore, probiotics, such as life bacteria providing health advantages, are a current strategy in the prevention or treatment of vaginitis, including BV. However, there is a low level of evidence that probiotics after ingestion could really colonize the vagina. In particular, no study evidenced that L. crispatus after ingestion can colonize vagina. Therefore, the current study explored the capacity of Biovaginil® (NTC, Milan, Italy) dietary supplement containing Lactobacillus crispatus NTCVAG04 and vitamin A to colonize the gut and vagina in women with a history of vaginitis/vaginosis.

Methods: Twenty fertile females (mean age 34.0 years) were enrolled in the study. Rectal and vaginal swabs were collected at baseline and after the first and second cycle of Biovaginil®. Each cycle lasted 14 days within two consecutive menstrual periods.

Results: Seven women were excluded from the analysis because the samples were technically not evaluable. One woman dropped out because of mild adverse event. At the end of the study, nine women (75%) had positive rectal swab for L. crispatus NTCVAG04, and 8 of them also had positive vaginal swab.

Conclusions: The current study provided the first evidence that L. crispatus NTCVAG04, administered by two Biovaginil® courses, colonized both the gut and vagina. Moreover, the L. crispatus NTCVAG04 strain could be considered the archetype of a new class of oral probiotics that actively colonize the vagina, and that could be called "colpobiotics."

背景:基因组方法深刻地改变了微生物学的观点,主要涉及微生物群的鉴定。在这方面,一些微生物在健康的阴道中定植。阴道炎是一种常见的妇科疾病,包括细菌性阴道病(BV),通常由局部生态失调(如微生物群失衡)引起。乳酸杆菌是在健康阴道中定植的最常见的细菌,因此可以保证局部的生态系统。特别是,L.crispatus的阴道定植与BV的低易感性有关。因此,益生菌,如提供健康优势的生命细菌,是目前预防或治疗阴道炎(包括BV)的一种策略。然而,摄入益生菌后确实可以在阴道定植的证据很少。特别是,没有研究证明摄入后的脆乳杆菌可以在阴道定植。因此,本研究探讨了含有脆乳杆菌NTCVAG04和维生素A的Biovaginail®(NTC,意大利米兰)膳食补充剂在有阴道炎/阴道病病史的女性肠道和阴道定植的能力。在基线以及Biovaginail®的第一个和第二个周期后采集直肠和阴道拭子。在连续两个月经周期内,每个周期持续14天。结果:7名女性被排除在分析之外,因为这些样本在技术上无法评估。一名女性因轻度不良事件退出。在研究结束时,9名女性(75%)的直肠拭子对卷曲乳杆菌NTCVAG04呈阳性,其中8名女性的阴道拭子也呈阳性。结论:目前的研究首次证明,通过两个Biovaginal®疗程给药的L.crispatus NTCVAG04在肠道和阴道均定植。此外,L.crispatus NTCVAG04菌株可以被认为是一类新的口服益生菌的原型,这种益生菌可以主动定植于阴道,可以被称为“阴道益生菌”
{"title":"Vaginal colonization of women after oral administration of Lactobacillus crispatus strain NTCVAG04 from the human microbiota.","authors":"Vincenzo DE Leo,&nbsp;Elisa Lazzeri,&nbsp;Laura Governini,&nbsp;Anna M Cuppone,&nbsp;Lorenzo Colombini,&nbsp;Lucia Teodori,&nbsp;Giorgio Ciprandi,&nbsp;Francesco Iannelli,&nbsp;Gianni Pozzi","doi":"10.23736/S2724-606X.22.05087-4","DOIUrl":"10.23736/S2724-606X.22.05087-4","url":null,"abstract":"<p><strong>Background: </strong>The genomic approach has deeply changed the microbiology perspective, mainly concerning the microbioma identification. In this regard, some microbes colonize the healthy vagina. Vaginitis is a common gynecological ailment and includes bacterial vaginosis (BV), usually caused by local dysbiosis, such as a microbiota imbalance. Lactobacilli are the most prevalent bacteria colonizing the healthy vagina, so guaranteeing local eubiosis. In particular, vaginal colonization by L. crispatus is associated with low susceptibility to BV. Therefore, probiotics, such as life bacteria providing health advantages, are a current strategy in the prevention or treatment of vaginitis, including BV. However, there is a low level of evidence that probiotics after ingestion could really colonize the vagina. In particular, no study evidenced that L. crispatus after ingestion can colonize vagina. Therefore, the current study explored the capacity of Biovaginil<sup>®</sup> (NTC, Milan, Italy) dietary supplement containing Lactobacillus crispatus NTCVAG04 and vitamin A to colonize the gut and vagina in women with a history of vaginitis/vaginosis.</p><p><strong>Methods: </strong>Twenty fertile females (mean age 34.0 years) were enrolled in the study. Rectal and vaginal swabs were collected at baseline and after the first and second cycle of Biovaginil<sup>®</sup>. Each cycle lasted 14 days within two consecutive menstrual periods.</p><p><strong>Results: </strong>Seven women were excluded from the analysis because the samples were technically not evaluable. One woman dropped out because of mild adverse event. At the end of the study, nine women (75%) had positive rectal swab for L. crispatus NTCVAG04, and 8 of them also had positive vaginal swab.</p><p><strong>Conclusions: </strong>The current study provided the first evidence that L. crispatus NTCVAG04, administered by two Biovaginil<sup>®</sup> courses, colonized both the gut and vagina. Moreover, the L. crispatus NTCVAG04 strain could be considered the archetype of a new class of oral probiotics that actively colonize the vagina, and that could be called \"colpobiotics.\"</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41136465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Unilateral hydroureteronephrosis after introduction of a levonorgestrel-releasing intrauterine system: a case report and literature review. 应用左炔诺孕酮宫内释放系统后单侧输尿管积水性肾病:病例报告和文献复习。
IF 1.8 Q2 Medicine Pub Date : 2023-10-01 Epub Date: 2022-10-18 DOI: 10.23736/S2724-606X.22.05112-0
Francesco G Martire, Matteo Giorgi, Luca Labanca, Gabriele Centini, Francesco Catania, Caterina Exacoustos, Errico Zupi, Lucia Lazzeri

Insertion of a LNG-Intra-uterine System (LNG-IUS) has many gynecological indications. The approved indications worldwide are contraception, treatment of abnormal uterine bleeding depending on not organic disease, and endometrial protection in case of an estrogenic therapy. Instead adenomyosis, fibroids, and fertility-sparing management of endometrial hyperplasia or early endometrial cancer in patients with desire of pregnancy are off label indications. Hydroureteronephrosis is an uncommon complication during LNG-IUS insertion. There are few cases described in the literature. The first diagnostic approach for this complication is an abdominal-pelvic ultrasound scan to identify the abnormal position of the device. Diagnostic management includes computed tomography (CT) or magnetic resonance imaging (MRI), which are necessary to confirm hydroureteronephrosis and to assess the exact location of the LNG-IUS in the abdomen. A minimally invasive approach is the standard of care with the removal of the device, while the therapeutic management of the hydroureteronephrosis depends on ureteral and kidney involvement. We report the history of a dislocated LNG-IUS in the left paracervical space with subsequent ipsilateral hydroureteronephrosis. In our case we removed the device through hysteroscopy and later inserted a J-J stent. Follow-up at three months revealed the persistence of left hydroureteronephrosis, so we performed ureter reimplantation. We also performed a review of the literature to analyze common diagnostic and therapeutic pathways for this rare complication.

插入LNG子宫内系统(LNG-IUS)有许多妇科适应症。世界范围内批准的适应症包括避孕、非器质性疾病引起的异常子宫出血的治疗以及雌激素治疗时的子宫内膜保护。相反,渴望怀孕的患者的子宫内膜增生或早期子宫内膜癌症的子宫腺肌症、类纤维瘤和保留受精治疗是标签外适应症。输尿管积水性肾病是LNG-IUS置入术中不常见的并发症。文献中描述的案例很少。这种并发症的第一种诊断方法是腹部-骨盆超声扫描,以确定设备的异常位置。诊断管理包括计算机断层扫描(CT)或磁共振成像(MRI),这是确认输尿管积水性肾病和评估LNG-IUS在腹部的确切位置所必需的。微创方法是移除装置的标准护理方法,而输尿管积水性肾病的治疗管理取决于输尿管和肾脏的介入。我们报告了左颈旁间隙LNG-IUS移位并随后发生同侧输尿管积水性肾病的病史。在我们的病例中,我们通过宫腔镜取出了该装置,随后插入了J-J支架。三个月的随访显示左侧输尿管积水性肾病持续存在,因此我们进行了输尿管再植入术。我们还对文献进行了回顾,以分析这种罕见并发症的常见诊断和治疗途径。
{"title":"Unilateral hydroureteronephrosis after introduction of a levonorgestrel-releasing intrauterine system: a case report and literature review.","authors":"Francesco G Martire,&nbsp;Matteo Giorgi,&nbsp;Luca Labanca,&nbsp;Gabriele Centini,&nbsp;Francesco Catania,&nbsp;Caterina Exacoustos,&nbsp;Errico Zupi,&nbsp;Lucia Lazzeri","doi":"10.23736/S2724-606X.22.05112-0","DOIUrl":"10.23736/S2724-606X.22.05112-0","url":null,"abstract":"<p><p>Insertion of a LNG-Intra-uterine System (LNG-IUS) has many gynecological indications. The approved indications worldwide are contraception, treatment of abnormal uterine bleeding depending on not organic disease, and endometrial protection in case of an estrogenic therapy. Instead adenomyosis, fibroids, and fertility-sparing management of endometrial hyperplasia or early endometrial cancer in patients with desire of pregnancy are off label indications. Hydroureteronephrosis is an uncommon complication during LNG-IUS insertion. There are few cases described in the literature. The first diagnostic approach for this complication is an abdominal-pelvic ultrasound scan to identify the abnormal position of the device. Diagnostic management includes computed tomography (CT) or magnetic resonance imaging (MRI), which are necessary to confirm hydroureteronephrosis and to assess the exact location of the LNG-IUS in the abdomen. A minimally invasive approach is the standard of care with the removal of the device, while the therapeutic management of the hydroureteronephrosis depends on ureteral and kidney involvement. We report the history of a dislocated LNG-IUS in the left paracervical space with subsequent ipsilateral hydroureteronephrosis. In our case we removed the device through hysteroscopy and later inserted a J-J stent. Follow-up at three months revealed the persistence of left hydroureteronephrosis, so we performed ureter reimplantation. We also performed a review of the literature to analyze common diagnostic and therapeutic pathways for this rare complication.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40338888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menstrual cycle alterations in reproductive age women after anti COVID-19 vaccination. A survey in 419 Italian women and quality of life and sexual function evaluation. 接种抗COVID-19疫苗后育龄妇女月经周期的改变一项调查对419名意大利妇女的生活质量和性功能进行了评价。
IF 1.8 Q2 Medicine Pub Date : 2023-09-15 DOI: 10.23736/S2724-606X.23.05347-2
Melania Loggia, Anna DI Pinto, Claudia Morgani, Giorgia Cardella, Alessia Contadini, Pier L Palazzetti, Francesca Macrì, Paolo R Moro, Vincenzo Spina, Andrea Morciano, Herbert C Valensise, Michele C Schiavi

Background: Pharmacovigilance agencies did not collect data regarding menstrual changes after COVID-19 vaccination even if many women experienced it. Our aim was to evaluate whether COVID-19 vaccination is associated with secondary changes in menstrual cycle and to assess both quality of life (QoL) and sexual function (SF).

Methods: This study is a retrospective analysis referred to our Department from January 2021 to December 2021. The study cohort responded to same questionnaires before the second dose of vaccination (referring to previous 3 months) and 3 months after that (referring to three menstrual cycles after full-dose vaccination). The surveys administered were FSFI, FSDS, SF-36, MEDI-Q and the VAS-scale for dysmenorrhea.

Results: Four-hundred-nineteen vaccinated women were included in the study. The survey did not show a significant change in menstrual cycle length before and after COVID-19 vaccine (5.88±3.67 vs. 4.97±2.89, P=0.21); the interval between periods was significantly higher after a full-cycle vaccination (28.32±7.34 vs. 32.38±7.45, P<0.02); 32 patients (7.6%) developed amenorrhea after the second dose; VAS Scale did not change significantly (median range 3 (3-5) vs. 4 (3-6), P=0.20). MEDI-Q did not show significant variations before and after the vaccination (43.21±11.65 vs. 40.28±9.88, P=0.35). QoL and SF did not change significantly (FSFI median 27 [24-29] vs. 28 [25-30], P=0.12, FSDS median 9 [5-11] vs. 8 [4-12], P=0.22), SF-36 median 81 [70-85] vs. 82 [72-86], P=0.43).

Conclusions: COVID-19 vaccination is associated with a significant change in intervals between menstrual cycles without other alterations in menstrual characteristics, in QoL or SF.

背景:药物警戒机构没有收集关于COVID-19疫苗接种后月经变化的数据,即使许多妇女都经历了这种变化。我们的目的是评估COVID-19疫苗接种是否与月经周期的继发性改变有关,并评估生活质量(QoL)和性功能(SF)。方法:本研究是对我科2021年1月至2021年12月的回顾性分析。研究队列在第二次接种前(参照前3个月)和接种后3个月(参照全剂量接种后的3个月经周期)回答相同的问卷。采用FSFI、FSDS、SF-36、medium - q和痛经vas量表进行调查。结果:研究中包括了419名接种疫苗的妇女。调查显示,接种新冠病毒疫苗前后月经周期长度无显著变化(5.88±3.67∶4.97±2.89,P=0.21);全周期疫苗接种后月经间隔时间明显增加(28.32±7.34 vs. 32.38±7.45)。结论:COVID-19疫苗接种与月经周期间隔时间显著改变相关,而月经特征、生活质量或SF没有其他改变。
{"title":"Menstrual cycle alterations in reproductive age women after anti COVID-19 vaccination. A survey in 419 Italian women and quality of life and sexual function evaluation.","authors":"Melania Loggia,&nbsp;Anna DI Pinto,&nbsp;Claudia Morgani,&nbsp;Giorgia Cardella,&nbsp;Alessia Contadini,&nbsp;Pier L Palazzetti,&nbsp;Francesca Macrì,&nbsp;Paolo R Moro,&nbsp;Vincenzo Spina,&nbsp;Andrea Morciano,&nbsp;Herbert C Valensise,&nbsp;Michele C Schiavi","doi":"10.23736/S2724-606X.23.05347-2","DOIUrl":"https://doi.org/10.23736/S2724-606X.23.05347-2","url":null,"abstract":"<p><strong>Background: </strong>Pharmacovigilance agencies did not collect data regarding menstrual changes after COVID-19 vaccination even if many women experienced it. Our aim was to evaluate whether COVID-19 vaccination is associated with secondary changes in menstrual cycle and to assess both quality of life (QoL) and sexual function (SF).</p><p><strong>Methods: </strong>This study is a retrospective analysis referred to our Department from January 2021 to December 2021. The study cohort responded to same questionnaires before the second dose of vaccination (referring to previous 3 months) and 3 months after that (referring to three menstrual cycles after full-dose vaccination). The surveys administered were FSFI, FSDS, SF-36, MEDI-Q and the VAS-scale for dysmenorrhea.</p><p><strong>Results: </strong>Four-hundred-nineteen vaccinated women were included in the study. The survey did not show a significant change in menstrual cycle length before and after COVID-19 vaccine (5.88±3.67 vs. 4.97±2.89, P=0.21); the interval between periods was significantly higher after a full-cycle vaccination (28.32±7.34 vs. 32.38±7.45, P<0.02); 32 patients (7.6%) developed amenorrhea after the second dose; VAS Scale did not change significantly (median range 3 (3-5) vs. 4 (3-6), P=0.20). MEDI-Q did not show significant variations before and after the vaccination (43.21±11.65 vs. 40.28±9.88, P=0.35). QoL and SF did not change significantly (FSFI median 27 [24-29] vs. 28 [25-30], P=0.12, FSDS median 9 [5-11] vs. 8 [4-12], P=0.22), SF-36 median 81 [70-85] vs. 82 [72-86], P=0.43).</p><p><strong>Conclusions: </strong>COVID-19 vaccination is associated with a significant change in intervals between menstrual cycles without other alterations in menstrual characteristics, in QoL or SF.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10244317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What's new on female genital mutilation/cutting? Recent findings about urogynecologic complications, psychological issues, and obstetric outcomes. 切割女性生殖器官有什么新进展?关于泌尿妇科并发症、心理问题和产科结局的最新发现。
IF 1.8 Q2 Medicine Pub Date : 2023-08-04 DOI: 10.23736/S2724-606X.23.05344-7
Alessandro Libretti, Christian Corsini, Valentino Remorgida

Female genital mutilation/cutting (FGM/C or FGM) are injuries to the female genital organs for non-medical reasons. Every year, over 4 million girls are at risk of FGM. Complications of this practice are very common and some of them are still under investigation. The purpose of this short narrative review is to highlight and summarize the main ones. Psychologic and psychiatric sequelae, chronic vulvar pain, urogenital symptoms, pelvic organs prolapse, sexual disfunction, cervical dysplasia and infections resulted as chronic sequalae of FGM. Severe pain, excessive bleeding, and tissues swelling are acute consequences of FGM. Rates of caesarean section, time of second stage of delivery, post-partum blood loss (but not major hemorrhage), peri-clitoral and perineal injuries and episiotomy rates are higher in pregnant women with FGM, when compared with those non victims of mutilation. The female genital mutilation practice is often cause of severe urogynecologic, psychologic and obstetrics sequelae. Although several studies have been carried out on FMG complications and treatments, long term sequelae are still very common and deserve major attention and further research.

切割/切割女性生殖器官(FGM/C或FGM)是指出于非医疗原因对女性生殖器官造成的伤害。每年有400多万女孩面临女性生殖器切割的风险。这种做法的并发症很常见,其中一些仍在调查中。这篇简短的叙述性回顾的目的是突出和总结主要内容。女性生殖器切割的慢性后遗症包括心理和精神后遗症、慢性外阴疼痛、泌尿生殖系统症状、盆腔器官脱垂、性功能障碍、宫颈发育不良和感染。剧烈疼痛、大出血和组织肿胀是女性生殖器切割的急性后果。剖腹产率、第二阶段分娩时间、产后失血(但不是大出血)、阴蒂周围和会阴损伤以及外阴切开术的发生率在遭受切割的孕妇中高于未遭受切割的孕妇。切割女性生殖器官的做法往往是造成严重的泌尿妇科,心理和产科后遗症。虽然对FMG的并发症和治疗方法进行了一些研究,但长期后遗症仍然非常普遍,值得重视和进一步研究。
{"title":"What's new on female genital mutilation/cutting? Recent findings about urogynecologic complications, psychological issues, and obstetric outcomes.","authors":"Alessandro Libretti,&nbsp;Christian Corsini,&nbsp;Valentino Remorgida","doi":"10.23736/S2724-606X.23.05344-7","DOIUrl":"https://doi.org/10.23736/S2724-606X.23.05344-7","url":null,"abstract":"<p><p>Female genital mutilation/cutting (FGM/C or FGM) are injuries to the female genital organs for non-medical reasons. Every year, over 4 million girls are at risk of FGM. Complications of this practice are very common and some of them are still under investigation. The purpose of this short narrative review is to highlight and summarize the main ones. Psychologic and psychiatric sequelae, chronic vulvar pain, urogenital symptoms, pelvic organs prolapse, sexual disfunction, cervical dysplasia and infections resulted as chronic sequalae of FGM. Severe pain, excessive bleeding, and tissues swelling are acute consequences of FGM. Rates of caesarean section, time of second stage of delivery, post-partum blood loss (but not major hemorrhage), peri-clitoral and perineal injuries and episiotomy rates are higher in pregnant women with FGM, when compared with those non victims of mutilation. The female genital mutilation practice is often cause of severe urogynecologic, psychologic and obstetrics sequelae. Although several studies have been carried out on FMG complications and treatments, long term sequelae are still very common and deserve major attention and further research.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is vestibulodynia a nociplastic pain syndrome? 前庭痛是一种伤害性疼痛综合征吗?
IF 1.8 Q2 Medicine Pub Date : 2023-08-01 DOI: 10.23736/S2724-606X.22.05056-4
Filippo Murina
{"title":"Is vestibulodynia a nociplastic pain syndrome?","authors":"Filippo Murina","doi":"10.23736/S2724-606X.22.05056-4","DOIUrl":"https://doi.org/10.23736/S2724-606X.22.05056-4","url":null,"abstract":"","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9913768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CO2 fiber laser vaporization for endometrioma treatment results in preserved ovarian responsiveness and improved embryo quality in infertile women undergoing ART. CO2纤维激光汽化治疗子宫内膜异位瘤对接受抗逆转录病毒治疗的不孕症妇女的卵巢反应性和胚胎质量均有改善。
IF 1.8 Q2 Medicine Pub Date : 2023-08-01 DOI: 10.23736/S2724-606X.22.05188-0
Massimo Candiani, Stefano M Ferrari, Noemi Salmeri, Carolina Dolci, Roberta Villanacci, Ludovica Bartiromo, Matteo Schimberni, Iacopo Tandoi, Jessica Ottolina

Background: Infertile women carrying ovarian endometriomas can be managed either with surgery or by in-vitro fertilization (IVF). The aim of this study was to compare ovarian responsiveness to controlled ovarian stimulation (COS) in assisted reproduction techniques (ART) in infertile women carrying small intact endometriomas and those managed by endometrioma cystectomy or CO2 fiber laser ablation.

Methods: Retrospective case-control study of prospectively collected data including women underwent ART for endometriosis-related infertility. The study group consisted of infertile women undergoing endometriomas CO2 fiber laser vaporization before ART ("ART after laser CO2" group). Controls were infertile women with endometrioma managed by cystectomy before ART ("ART after cystectomy" group) and infertile women with small endometriomas undergoing ART as first approach ("ART only" group).

Results: Of the 86 included patients, 27 (31.4%) belonged to "ART after laser CO2" group, 37 (43%) to "ART after cystectomy" group and 22 (25.6%) to "ART only" group. Surgical groups had larger endometriomas than patients referred to "ART only" group. No between-groups differences were observed in terms of COS protocol, gonadotropins starting and total doses and length of COS. While women belonged to "ART after cystectomy" group had fewer recruited follicles (P=0.014), oocytes (P=0.042), MII oocytes (P=0.042) and formed embryos (P=0.004) compared to women of "ART only" group, no significant differences were found between patients of "ART only" group "ART after laser CO2" group. A greater number of good-quality embryos were observed in surgical groups. No between-groups differences were found in clinical pregnancy rates.

Conclusions: Our results demonstrate encouraging findings on IVF/ICSI outcomes after laser CO2 endometrioma ablation in terms of both quantity and quality of developed embryos.

背景:患有卵巢子宫内膜异位瘤的不孕妇女可以通过手术或体外受精(IVF)进行治疗。本研究的目的是比较携带小完整子宫内膜异位瘤的不孕妇女和子宫内膜异位瘤膀胱切除术或CO2纤维激光消融治疗的妇女在辅助生殖技术(ART)中卵巢对控制卵巢刺激(COS)的反应性。方法:回顾性病例对照研究,前瞻性收集接受ART治疗子宫内膜异位症相关不孕症的妇女资料。研究组由接受子宫内膜异位瘤CO2纤维激光汽化前的不孕妇女组成(“CO2激光后的ART”组)。对照组为接受ART前膀胱切除术治疗的子宫内膜异位瘤的不孕妇女(“膀胱切除术后ART”组)和接受ART为第一途径的小子宫内膜异位瘤的不孕妇女(“仅ART”组)。结果86例患者中,“CO2激光后ART”组27例(31.4%),“膀胱切除术后ART”组37例(43%),“单纯ART”组22例(25.6%)。手术组的子宫内膜异位瘤大于“仅ART”组。在COS方案、促性腺激素起始剂量和总剂量以及COS持续时间方面,两组间无差异。与“单纯ART”组相比,“膀胱切除术后ART”组女性的再生卵泡(P=0.014)、卵母细胞(P=0.042)、MII卵母细胞(P=0.042)和形成胚胎(P=0.004)较少,而“单纯ART”组和“激光CO2后ART”组患者之间无显著差异。在手术组中观察到更多的优质胚胎。临床妊娠率组间无差异。结论:我们的研究结果显示了激光CO2子宫内膜瘤消融后IVF/ICSI结果在发育胚胎数量和质量方面的令人鼓舞的发现。
{"title":"CO2 fiber laser vaporization for endometrioma treatment results in preserved ovarian responsiveness and improved embryo quality in infertile women undergoing ART.","authors":"Massimo Candiani,&nbsp;Stefano M Ferrari,&nbsp;Noemi Salmeri,&nbsp;Carolina Dolci,&nbsp;Roberta Villanacci,&nbsp;Ludovica Bartiromo,&nbsp;Matteo Schimberni,&nbsp;Iacopo Tandoi,&nbsp;Jessica Ottolina","doi":"10.23736/S2724-606X.22.05188-0","DOIUrl":"https://doi.org/10.23736/S2724-606X.22.05188-0","url":null,"abstract":"<p><strong>Background: </strong>Infertile women carrying ovarian endometriomas can be managed either with surgery or by in-vitro fertilization (IVF). The aim of this study was to compare ovarian responsiveness to controlled ovarian stimulation (COS) in assisted reproduction techniques (ART) in infertile women carrying small intact endometriomas and those managed by endometrioma cystectomy or CO<inf>2</inf> fiber laser ablation.</p><p><strong>Methods: </strong>Retrospective case-control study of prospectively collected data including women underwent ART for endometriosis-related infertility. The study group consisted of infertile women undergoing endometriomas CO<inf>2</inf> fiber laser vaporization before ART (\"ART after laser CO<inf>2</inf>\" group). Controls were infertile women with endometrioma managed by cystectomy before ART (\"ART after cystectomy\" group) and infertile women with small endometriomas undergoing ART as first approach (\"ART only\" group).</p><p><strong>Results: </strong>Of the 86 included patients, 27 (31.4%) belonged to \"ART after laser CO<inf>2</inf>\" group, 37 (43%) to \"ART after cystectomy\" group and 22 (25.6%) to \"ART only\" group. Surgical groups had larger endometriomas than patients referred to \"ART only\" group. No between-groups differences were observed in terms of COS protocol, gonadotropins starting and total doses and length of COS. While women belonged to \"ART after cystectomy\" group had fewer recruited follicles (P=0.014), oocytes (P=0.042), MII oocytes (P=0.042) and formed embryos (P=0.004) compared to women of \"ART only\" group, no significant differences were found between patients of \"ART only\" group \"ART after laser CO<inf>2</inf>\" group. A greater number of good-quality embryos were observed in surgical groups. No between-groups differences were found in clinical pregnancy rates.</p><p><strong>Conclusions: </strong>Our results demonstrate encouraging findings on IVF/ICSI outcomes after laser CO<inf>2</inf> endometrioma ablation in terms of both quantity and quality of developed embryos.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Cryopreservation of ovarian tissue: the biggest challenge of oncofertility. 卵巢组织低温保存:肿瘤生育的最大挑战。
IF 1.8 Q2 Medicine Pub Date : 2023-08-01 DOI: 10.23736/S2724-606X.22.05066-7
Federica Cariati, Luigi Carbone, Giuseppe G Iorio, Alessandro Conforti, Anna Capasso, Francesca Bagnulo, Stefania R Peluso, Roberta Giuliano, Ida Strina, Carlo Alviggi
Survival rates after cancer diagnosis and treatment have been raising through the last decades. Nowadays, oncofertility represents a useful strategy for young women affected by cancer to preserve their ovarian function and their family planning opportunity. Apart from more diffused techniques as cryopreservation of mature oocytes after controlled ovarian stimulation and gonadal downregulation with GnRH agonist depots, the cryopreservation of the cortical region of the ovarian tissue, which contains 90% of the follicular reserve, and later autologous transplant represent a possible and intriguing strategy. Nonetheless, the safety of the procedure is still a matter of debate and is a topic of great interest in both oncologic and reproductive fields. Especially, in order to improve the efficacy of the strategy the open questions are 1) how to search for malignant cells, 2) slow freezing vs. vitrification, 3) state of the art on the "artificial ovary". The aim of this review is to summarize the recent advances in ovarian tissue cryopreservation and present future perspectives.
在过去的几十年里,癌症诊断和治疗后的存活率一直在提高。如今,对于受癌症影响的年轻女性来说,肿瘤生育是一种有用的策略,可以保护她们的卵巢功能和计划生育机会。除了使用促性腺激素释放激素激动剂储存库在控制卵巢刺激和性腺下调后冷冻保存成熟卵母细胞等更广泛的技术外,冷冻保存卵巢组织的皮质区域(包含90%的卵泡储备)和随后的自体移植是一种可能的和有趣的策略。尽管如此,手术的安全性仍然是一个有争议的问题,是肿瘤学和生殖学领域非常感兴趣的话题。特别是,为了提高策略的有效性,需要解决的问题是:1)如何搜索恶性细胞;2)缓慢冷冻vs.玻璃化;3)关于“人工卵巢”的最新研究进展。本文综述了近年来卵巢组织冷冻保存的研究进展,并对其发展前景进行了展望。
{"title":"Cryopreservation of ovarian tissue: the biggest challenge of oncofertility.","authors":"Federica Cariati,&nbsp;Luigi Carbone,&nbsp;Giuseppe G Iorio,&nbsp;Alessandro Conforti,&nbsp;Anna Capasso,&nbsp;Francesca Bagnulo,&nbsp;Stefania R Peluso,&nbsp;Roberta Giuliano,&nbsp;Ida Strina,&nbsp;Carlo Alviggi","doi":"10.23736/S2724-606X.22.05066-7","DOIUrl":"https://doi.org/10.23736/S2724-606X.22.05066-7","url":null,"abstract":"Survival rates after cancer diagnosis and treatment have been raising through the last decades. Nowadays, oncofertility represents a useful strategy for young women affected by cancer to preserve their ovarian function and their family planning opportunity. Apart from more diffused techniques as cryopreservation of mature oocytes after controlled ovarian stimulation and gonadal downregulation with GnRH agonist depots, the cryopreservation of the cortical region of the ovarian tissue, which contains 90% of the follicular reserve, and later autologous transplant represent a possible and intriguing strategy. Nonetheless, the safety of the procedure is still a matter of debate and is a topic of great interest in both oncologic and reproductive fields. Especially, in order to improve the efficacy of the strategy the open questions are 1) how to search for malignant cells, 2) slow freezing vs. vitrification, 3) state of the art on the \"artificial ovary\". The aim of this review is to summarize the recent advances in ovarian tissue cryopreservation and present future perspectives.","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9928577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Minerva obstetrics and gynecology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1